Michael Schenker

17.5k total citations · 2 hit papers
113 papers, 1.7k citations indexed

About

Michael Schenker is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Michael Schenker has authored 113 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Oncology, 44 papers in Pulmonary and Respiratory Medicine and 29 papers in Surgery. Recurrent topics in Michael Schenker's work include Cancer Immunotherapy and Biomarkers (46 papers), Lung Cancer Treatments and Mutations (19 papers) and Gastric Cancer Management and Outcomes (15 papers). Michael Schenker is often cited by papers focused on Cancer Immunotherapy and Biomarkers (46 papers), Lung Cancer Treatments and Mutations (19 papers) and Gastric Cancer Management and Outcomes (15 papers). Michael Schenker collaborates with scholars based in Romania, United States and France. Michael Schenker's co-authors include Lucjan Wyrwicz, Markus Moehler, Narikazu Boku, Se Hoon Park, Min‐Hee Ryu, Eric Van Cutsem, Ludovic Evesque, María Alsina, Eduardo Yañez Ruiz and Hyun Cheol Chung and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Michael Schenker

104 papers receiving 1.7k citations

Hit Papers

Phase III, randomised trial of avelumab versus physician’... 2018 2026 2020 2023 2018 2024 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
    2018 372 citations Eric Van Cutsem, Michael Schenker et al. Annals of Oncology profile →
  2. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
    2024 75 citations Peter R. Galle, Thomas Decaens et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Schenker Romania 20 1.1k 726 430 267 252 113 1.7k
Marcus Tan United States 19 1.1k 1.0× 386 0.5× 339 0.8× 306 1.1× 528 2.1× 52 1.8k
Fernanda Herrera Switzerland 19 625 0.5× 590 0.8× 243 0.6× 216 0.8× 257 1.0× 65 1.6k
Anna Koumarianou Greece 23 937 0.8× 327 0.5× 245 0.6× 305 1.1× 81 0.3× 114 1.7k
Fritz Lin United States 23 530 0.5× 517 0.7× 657 1.5× 511 1.9× 131 0.5× 51 1.9k
Yusuke Onozawa Japan 23 718 0.6× 902 1.2× 656 1.5× 239 0.9× 37 0.1× 129 1.7k
Shinkyo Yoon South Korea 18 565 0.5× 521 0.7× 173 0.4× 239 0.9× 90 0.4× 84 1.1k
Brian Weston United States 25 690 0.6× 1.0k 1.4× 1.1k 2.4× 316 1.2× 43 0.2× 112 1.9k
Ulf Petrausch Switzerland 23 1.1k 1.0× 289 0.4× 231 0.5× 289 1.1× 450 1.8× 62 1.6k
Ronald L. Richardson United States 27 1.1k 0.9× 949 1.3× 646 1.5× 588 2.2× 344 1.4× 79 2.3k
Stephan Probst Canada 20 660 0.6× 1.6k 2.2× 734 1.7× 113 0.4× 47 0.2× 109 2.4k

Countries citing papers authored by Michael Schenker

Since Specialization
Citations

This map shows the geographic impact of Michael Schenker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Schenker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Schenker more than expected).

Fields of papers citing papers by Michael Schenker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Schenker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Schenker. The network helps show where Michael Schenker may publish in the future.

Co-authorship network of co-authors of Michael Schenker

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Schenker. A scholar is included among the top collaborators of Michael Schenker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Schenker. Michael Schenker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ascierto, Paolo A., Michele Del Vecchio, Barbara Merelli, et al.. (2025). 1609P Final, 9-year results from the CheckMate 238 phase III trial of adjuvant nivolumab vs ipilimumab in resected stage IIIB–C or IV melanoma. Annals of Oncology. 36. S887–S888.
2.
Şurlin, Valeriu, et al.. (2025). The Role of Prophylactic Gastrectomy in Gastric Adenocarcinoma and Proximal Polyposis of the Stomach: A Systematic Review. Journal of Clinical Medicine. 14(7). 2522–2522.
3.
4.
Schenker, Michael, Begoña P. Valderrama, A. Bamias, et al.. (2025). 3068O Adjuvant nivolumab vs placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274. Annals of Oncology. 36. S1482–S1482.
5.
Pleşea, Iancu Emil, Cristian Virgil Lungulescu, Anca M. Barbu, et al.. (2024). Clinically Significant BRCA1 and BRCA2 Germline Variants in Breast Cancer—A Single-Center Experience. Cancers. 17(1). 39–39. 1 indexed citations
6.
7.
8.
Reck, Martin, Tudor–Eliade Ciuleanu, Michael Schenker, et al.. (2024). Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.. Journal of Clinical Oncology. 42(16_suppl). 8560–8560. 6 indexed citations
9.
Galsky, Matt D., Guru Sonpavde, Thomas Powles, et al.. (2024). Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.. Journal of Clinical Oncology. 42(16_suppl). 4509–4509. 11 indexed citations
10.
Galle, Peter R., Thomas Decaens, Masatoshi Kudo, et al.. (2024). Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.. Journal of Clinical Oncology. 42(17_suppl). LBA4008–LBA4008. 75 indexed citations breakdown →
11.
Gray, Jhanelle E., Michael Schenker, Mehmet Alı Nahıt Şendur, et al.. (2024). MA11.07 Pembrolizumab Plus Maintenance Olaparib as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 KEYLYNK-006 Study. Journal of Thoracic Oncology. 19(10). S98–S98. 1 indexed citations
12.
Heijden, Michiel S. van der, Guru Sonpavde, Thomas Powles, et al.. (2023). LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial. Annals of Oncology. 34. S1341–S1341. 9 indexed citations
13.
Simion, Laurenţiu, Simona Ruxandra Volovăț, Michael Schenker, et al.. (2022). HER2 Positive Breast Cancer Therapy - A Challenging and Continuously Moving Pathway – A Narrative Literature Review. Archives of Breast Cancer. 10(1). 15–25. 2 indexed citations
14.
Bajorin, Dean F., J. Alfred Witjes, Jürgen E. Gschwend, et al.. (2021). First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).. Journal of Clinical Oncology. 39(6_suppl). 391–391. 30 indexed citations
15.
Gheonea, Dan Ionuț, et al.. (2021). The Prognostic Correlation of Heart Rate Variability at Diagnosis with Survival of Patients with Hepatocellular Carcinoma. Diagnostics. 11(5). 890–890. 9 indexed citations
16.
Sfredel, Veronica, et al.. (2021). Assessment of Epinephrine and Norepinephrine in Gastric Carcinoma. International Journal of Molecular Sciences. 22(4). 2042–2042. 13 indexed citations
17.
Thatcher, Nicholas, Jerome H. Goldschmidt, Michael Thomas, et al.. (2019). Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study. Clinical Cancer Research. 25(7). 2088–2095. 43 indexed citations
18.
Schenker, Michael, et al.. (2018). Procalcitonin als Instrument zur Erfolgsmessung der Therapie einer schweren Sepsis: Eine Untersuchung mit klinischen Routinedaten. Medizinische Klinik - Intensivmedizin und Notfallmedizin. 113(7). 533–541. 1 indexed citations
19.
Iordache, Sevastiţa, Adrian Săftoiu, Claudia Valentina Georgescu, et al.. (2010). Vascular endothelial growth factor expression and microvessel density--two useful tools for the assessment of prognosis and survival in gastric cancer patients.. PubMed. 19(2). 135–9. 35 indexed citations
20.
Schenker, Michael, et al.. (2010). Recent data about the role of human papillomavirus (HPV) in oncogenesis of head and neck cancer.. PubMed. 51(3). 437–40. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marcus Tan Breakdown of academic impact, for papers by Fernanda Herrera Breakdown of academic impact, for papers by Anna Koumarianou Breakdown of academic impact, for papers by Fritz Lin Breakdown of academic impact, for papers by Yusuke Onozawa Breakdown of academic impact, for papers by Shinkyo Yoon Breakdown of academic impact, for papers by Brian Weston Breakdown of academic impact, for papers by Ulf Petrausch Breakdown of academic impact, for papers by Ronald L. Richardson Breakdown of academic impact, for papers by Stephan Probst
Rankless by CCL
2026